Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.55 -0.91 (-1.88%)
Official Closing Price Updated: 4:10 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
News headline image
Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle? ↗
The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line. 
Via The Motley Fool
News headline image
Can AI Drive Peloton's Comeback? ↗
The market is hopping with interesting news. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗
Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026. 
Via Benzinga
News headline image
Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets ↗
Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this... 
Via Benzinga
Topics Bankruptcy
News headline image
Price Over Earnings Overview: Novo Nordisk ↗
 
Via Benzinga
News headline image
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation. 
Via Benzinga
Topics ETFs
News headline image
Novo Nordisk Leans Into Affordability Amid Rising Competition ↗
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout. 
Via Benzinga
News headline image
Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control ↗
Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation. 
Via Benzinga
News headline image
Omeros (OMER) Q3 2025 Earnings Call Transcript ↗
Omeros (OMER) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Derivatives Earnings
News headline image
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration ↗
Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic. 
Via Investor's Business Daily
Topics Government
News headline image
Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound ↗
The Danish drugmaker has announced that this offer is applicable to cash-paying patients looking to purchase introductory doses of Wegovy and Ozempic. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? ↗
Healthcare stocks have far outperformed the broader market over the past month. 
Via The Motley Fool
Topics ETFs Government World Trade
News headline image
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? ↗
Investors will be watching what Trump makes happen. 
Via The Motley Fool
Topics Government
News headline image
Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market ↗
Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn. 
Via Benzinga
News headline image
Novo Nordisk Brings Back Former CEO To Lead Board ↗
Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday. 
Via Stocktwits
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Did Scholar Rock Soar 26% Today? ↗
The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 
Via Stocktwits
Topics Earnings
News headline image
Ozempic Maker Novo Nordisk Faces Board Shakeup ↗
Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market. 
Via Benzinga
News headline image
Is It Too Late to Buy Novo Nordisk After the Drop? ↗
Analysts still see 52% upside for Novo Nordisk -- find out whether its blockbuster drugs can spark a major rebound in 2025. 
Via The Motley Fool
News headline image
Why Is Everyone Talking About Novo Nordisk Stock? ↗
There is hardly a dull moment for the drugmaker these days. 
Via The Motley Fool
News headline image
Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO ↗
The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction. 
Via Stocktwits
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗
Via Stocktwits
News headline image
Korro Bio Early Trial Results Fall Short; Stock Hits New Low ↗
Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs. 
Via Benzinga
News headline image
Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report ↗
CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game. 
Via Stocktwits
News headline image
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership. 
Via Benzinga
News headline image
Mangoceuticals Shares Soar Pre-market After Partnering with Eli Lilly, Novo Nordisk To Sell Obesity Drugs ↗
The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines. 
Via Stocktwits
1 Incredible Reason to Buy LLY's Stock in November ↗
Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher. 
Via The Motley Fool
Topics Government World Trade
News headline image
Eli Lilly Soars: A Pharmaceutical Giant's Breakout Fueled by Blockbuster Drugs and Strategic Vision
INDIANAPOLIS, IN – November 12, 2025 – Eli Lilly and Company (NYSE: LLY) is experiencing a monumental stock breakout today, sending ripples across the global financial markets. The pharmaceutical... 
Via MarketMinute
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study. 
Via Benzinga
News headline image
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch ↗
Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.